Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
17.98
+0.25 (1.41%)
At close: Dec 12, 2025, 4:00 PM EST
17.30
-0.68 (-3.78%)
Pre-market: Dec 15, 2025, 4:00 AM EST
Pharming Group Revenue
Pharming Group had revenue of $97.30M in the quarter ending September 30, 2025, with 30.00% growth. In the year 2024, Pharming Group had annual revenue of $297.20M with 21.15% growth.
Revenue (ttm)
$297.20M
Revenue Growth
+21.15%
P/S Ratio
3.25
Revenue / Employee
$896,718
Employees
404
Market Cap
1.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 297.20M | 51.88M | 21.15% |
| Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
| Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
| Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
| Dec 31, 2020 | 212.17M | 22.53M | 11.88% |
| Dec 31, 2019 | 189.64M | 34.36M | 22.12% |
| Dec 31, 2018 | 155.29M | 47.75M | 44.40% |
| Dec 31, 2017 | 107.54M | 90.83M | 543.88% |
| Dec 31, 2016 | 16.70M | 4.94M | 42.05% |
| Dec 31, 2015 | 11.76M | -13.88M | -54.13% |
| Dec 31, 2014 | 25.63M | 16.22M | 172.36% |
| Dec 31, 2013 | 9.41M | -4.59M | -32.77% |
| Dec 31, 2012 | 14.00M | 10.12M | 260.60% |
| Dec 31, 2011 | 3.88M | 2.41M | 163.98% |
| Dec 31, 2010 | 1.47M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PHAR News
- 7 days ago - Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit - GlobeNewsWire
- 5 weeks ago - Pharming Group N.V. (PHAR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 7 weeks ago - Pharming Group to report third quarter 2025 financial results and provide business update on November 6 - GlobeNewsWire
- 2 months ago - Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio - GlobeNewsWire
- 2 months ago - Pharming Group provides update on previously announced G&A expense reduction plan - GlobeNewsWire
- 2 months ago - Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years - GlobeNewsWire
- 3 months ago - Pharming Group promoted to the Euronext AMX® index - GlobeNewsWire